AstraZeneca, one of the world’s leading pharmaceutical companies, has announced the launch of Evinova, a health-tech business that aims to bring digital solutions and artificial intelligence (AI) to clinical trials and improve health outcomes.
Evinova: A new way of conducting clinical trials
Evinova is a separate entity from AstraZeneca, but will leverage the company’s expertise and resources in the life sciences sector. Evinova will offer a range of services and products to help accelerate and optimize the design, execution, and analysis of clinical trials, as well as to enhance patient engagement and retention.
Evinova will use AI and advanced analytics to generate insights from real-world data, electronic health records, and wearable devices, and to enable adaptive and personalized trial protocols. Evinova will also use digital platforms and tools to streamline the operational aspects of clinical trials, such as site selection, recruitment, monitoring, and reporting.
Evinova’s vision is to transform clinical trials into a more efficient, effective, and patient-centric process, and to deliver better outcomes for patients, researchers, and regulators.
Evinova’s partners and customers
Evinova has already secured partnerships with two of the world’s largest contract research organizations (CROs), Parexel and Fortrea, which will work with Evinova to provide innovative solutions to their clients in the pharmaceutical and biotechnology industries.
Evinova will also collaborate with other stakeholders in the health-care ecosystem, such as academic institutions, health-care providers, payers, and regulators, to foster a culture of innovation and data-sharing in clinical research.
Evinova’s first customer is AstraZeneca itself, which will use Evinova’s services and products to enhance its own clinical trials across its therapeutic areas, such as oncology, cardiovascular, renal, and metabolic diseases.
Evinova’s impact and potential
Evinova’s launch comes at a time when the global health-care sector is facing unprecedented challenges and opportunities, such as the COVID-19 pandemic, the aging population, the rise of chronic diseases, and the emergence of new technologies.
Evinova’s CEO, Dr. James Smith, said that Evinova’s mission is to “harness the power of digital and AI to drive innovation and efficiency in clinical trials, and ultimately to improve health outcomes for patients around the world”.
Evinova’s Chief Scientific Officer, Dr. Maria Rodriguez, added that Evinova’s approach is to “combine the best of human and machine intelligence, and to leverage the vast amount of data that is available in the health-care domain, to create smarter and faster clinical trials”.
Evinova’s launch is expected to have a significant impact on the clinical research landscape, as it will reduce the cost and time of clinical trials, increase the quality and reliability of data, and enable more personalized and precise treatments.
Evinova’s launch also reflects AstraZeneca’s commitment to innovation and digital transformation, as the company has been investing heavily in AI and other emerging technologies to enhance its research and development, manufacturing, and commercial operations.